MedPath

To Explore the efficacy of drugs which increase the gastrointestinal motility in Diabetic Gastroparesis.

Not Applicable
Conditions
Health Condition 1: E114- Type 2 diabetes mellitus with neurological complications
Registration Number
CTRI/2020/08/027264
Lead Sponsor
AIIMS RISHIKESH
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

All known/diagnosed TYPE 2 diabetic patient with delayed oro cecal transit time (OCTT) diagnosed on lactulose hydrogen breath test

Exclusion Criteria

All Type2 diabetic patient -

-In whom gastro paresis is due to any drug intake like Narcotic pain medicines, Antidepressants Anticholinergics, amylin analogues.

-Who underwent vagotomy / gastric surgery

-Who have thyroid disorder (hypothyroidism) or parkinsonism

-Pregnant females

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To Explore the efficacy of prokinetic agents in Diabetic GastroparesisTimepoint: TO MEASURE THE CHANGE IN OCTT WITH LACTULOSE HYDROGEN BREATH TEST AFTER 1 MONTH OF DRUG.
Secondary Outcome Measures
NameTimeMethod
To explore the relative advantage of one over the other prokinetic agents in Diabetic gastroparesis patientsTimepoint: TO MEASURE THE CHANGE IN OCTT WITH LACTULOSE HYDROGEN BREATH TEST AFTER 1 MONTH OF DRUG.
© Copyright 2025. All Rights Reserved by MedPath